$EXEL Company News Biotechs still sliding, but
Post# of 88924
Posted On: 05/01/2014 9:30:10 AM
$EXEL Company News
Biotechs still sliding, but Wall Street says don't hit panic button just yet 2:43 p.m. March 26, 2014 - Russ Britt
HMA’s pre-emptive strike against ‘60 Minutes’ 5:44 p.m. Nov. 30, 2012 - Russ Britt
Chipotle vs. Taco Bell: testing Einhorn's thesis 6:37 a.m. Oct. 4, 2012 - The Trading Deck
Exelixis prices stock offering at 0.7% discount 12:21 p.m. Aug. 9, 2012 - MarketWatch.com
Exelixis slides 12% on stock, debt offering 3:39 p.m. Aug. 6, 2012 - Val Brickates Kennedy
FDA to speed Exelixis thyroid-cancer-drug review 6:35 a.m. July 30, 2012 - MarketWatch.com
Stocks to watch Thursday: GM, Agilent, NetApp 7:51 a.m. Feb. 16, 2012 - MarketWatch
Exelixis licenses cancer-drug R&D to Merck & Co. 8:26 a.m. Dec. 21, 2011 - MarketWatch.com
Loathe that investment theme? Perfect! 1:03 p.m. Nov. 8, 2011 - The Trading Deck
Exelixis plunges on drug study woes 12:05 p.m. Nov. 1, 2011 - Val Brickates Kennedy
Stocks to watch Tuesday: Exelixis, DirecTV, Leap 6:46 a.m. Nov. 1, 2011 - MarketWatch
Exelixis slides, Allstate up in after-hours trade 6:48 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis shares fall without FDA study commentary 6:05 p.m. Oct. 31, 2011 - Wallace Witkowski
Exelixis shares resume trading, drop 35% 5:44 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis rallies 21% on drug study 11:46 a.m. Oct. 24, 2011 - Val Brickates Kennedy
Icahn reports new stakes in Vector Group, El Paso 7:52 p.m. Aug. 15, 2011 - MarketWatch.com
ASCO studies shake up drug stocks 4:17 p.m. June 7, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 6:50 p.m. June 6, 2011 - Kate Gibson
Exelixis, Sunesis lead drug stocks lower 3:42 p.m. June 6, 2011 - Val Brickates Kennedy
Exelixis sinks 18% on drug-safety concerns 3:21 p.m. June 6, 2011 - Val Brickates Kennedy
Notable earnings after Thursday close 5:35 p.m. April 30, 2014 - Seeking Alpha
First Week Of June 21st Options Trading For Exelixis (EXEL) 11:19 a.m. April 23, 2014 - TheStreet.com
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog 10:43 a.m. April 2, 2014 - Zacks.com
Exelixis' Cometriq Approved in the EU - Analyst Blog 6:00 p.m. March 27, 2014 - Zacks.com
Trade-Ideas: Exelixis (EXEL) Is Today's "Dead Cat Bounce" Stock 9:45 a.m. March 27, 2014 - TheStreet.com
Interesting EXEL Put And Call Options For November 22nd 12:13 p.m. March 26, 2014 - TheStreet.com
Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis 11:42 a.m. March 26, 2014 - TheStreet.com
Exelixis Enters the Danger Zone 11:35 a.m. March 26, 2014 - 247WallSt.com
Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis Shares Decline 11:28 a.m. March 26, 2014 - benzinga.com
Exelixis Urged to Continue Studying Prostate Cancer Treatment 9:27 a.m. March 26, 2014 - The Wall Street Journal Interactive Edition
Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast 9:24 a.m. March 26, 2014 - benzinga.com
Stocks Hitting 52-Week Lows 9:22 a.m. March 26, 2014 - benzinga.com
Exelixis (EXEL) Trading With Heavy Volume Before Market Open 8:46 a.m. March 26, 2014 - TheStreet.com
Exelixis trial for prostate-cancer drug given OK to continue 7:37 a.m. March 26, 2014 - Seeking Alpha
4 Reasons To Be Bullish On Exelixis In The Near Term 10:11 a.m. March 25, 2014 - Seeking Alpha
'Mad Money' Lightning Round: I Want to Buy Time Warner 6:00 a.m. March 14, 2014 - TheStreet.com
Cramer's Lightning Round - I Don't Know What Annaly Is Up To (3/13/14) 5:23 a.m. March 14, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Us vs. Them 7:58 p.m. March 13, 2014 - TheStreet.com
Exelixis Q4 Loss In Line with Expectations - Analyst Blog 12:04 p.m. Feb. 21, 2014 - Zacks.com
Exelixis CEO Discusses Q4 2013 Results - Earnings Call Transcript 11:37 p.m. Feb. 20, 2014 - Seeking Alpha
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014 4:07 p.m. April 21, 2014 - BusinessWire - BZX
Thyroid Cancer Global Clinical Trials Review, H2, 2013 1:29 p.m. April 9, 2014 - PR Newswire - PRF
European Commission Approves Exelixis Inc.'s Therapy for Thyroid Cancer 2:01 p.m. April 4, 2014 - ACCESSWIRE
King Digital Crushed In Its First Day of Trading; Exelixis Shares Fall 40 Percent 12:11 a.m. March 27, 2014 - ACCESSWIRE
Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer 7:18 p.m. March 25, 2014 - BusinessWire - BZX
Cometriq(R) approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. 7:02 a.m. March 25, 2014 - Thomson Reuters ONE
Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma 6:01 a.m. March 25, 2014 - BusinessWire - BZX
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus 10:46 a.m. March 24, 2014 - PR Newswire - PRF
Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference 8:56 p.m. Feb. 26, 2014 - BusinessWire - BZX
Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results 5:15 p.m. Feb. 20, 2014 - BusinessWire - BZX
Exelixis Appoints Executive Vice President and General Counsel 6:27 p.m. Feb. 12, 2014 - BusinessWire - BZX
Exelixis Announces February 20th Webcast of Fourth Quarter and Full Year 2013 Financial Results Conference Call 5:35 p.m. Feb. 10, 2014 - BusinessWire - BZX
Exelixis Announces Webcasts of Investor Conference Presentations in February 6:48 p.m. Jan. 31, 2014 - BusinessWire - BZX
Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock 9:33 a.m. Jan. 23, 2014 - BusinessWire - BZX
Exelixis Launches Proposed Overnight Public Offering of Common Stock 5:01 p.m. Jan. 22, 2014 - BusinessWire - BZX
Honigman leads client to victory in U.S. Court of Appeals patent term adjustment ruling 8:08 a.m. Jan. 17, 2014 - GlobeNewswire
Unaudited Results, Partnerships, and Stock Price Movements - Research Report on Cubist, Novavax, Exelixis, BioCryst, and Foundation Medicine 9:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
Upcoming Conference Participations, Cash Dividends, and Share Price Movements - Research Report on Johnson & Johnson, Boston Scientific, NuVasive, Exelixis, and Healthways 9:00 a.m. Jan. 7, 2014 - PR Newswire
Clinical Study Results, Pending Applications, Trial Updates, and Discontinued Trials - Research Report on ICU Medical, Exelixis, Cempra, Exact Sciences, and Onconova 9:00 a.m. Dec. 25, 2013 - PR Newswire
Biotechs still sliding, but Wall Street says don't hit panic button just yet 2:43 p.m. March 26, 2014 - Russ Britt
HMA’s pre-emptive strike against ‘60 Minutes’ 5:44 p.m. Nov. 30, 2012 - Russ Britt
Chipotle vs. Taco Bell: testing Einhorn's thesis 6:37 a.m. Oct. 4, 2012 - The Trading Deck
Exelixis prices stock offering at 0.7% discount 12:21 p.m. Aug. 9, 2012 - MarketWatch.com
Exelixis slides 12% on stock, debt offering 3:39 p.m. Aug. 6, 2012 - Val Brickates Kennedy
FDA to speed Exelixis thyroid-cancer-drug review 6:35 a.m. July 30, 2012 - MarketWatch.com
Stocks to watch Thursday: GM, Agilent, NetApp 7:51 a.m. Feb. 16, 2012 - MarketWatch
Exelixis licenses cancer-drug R&D to Merck & Co. 8:26 a.m. Dec. 21, 2011 - MarketWatch.com
Loathe that investment theme? Perfect! 1:03 p.m. Nov. 8, 2011 - The Trading Deck
Exelixis plunges on drug study woes 12:05 p.m. Nov. 1, 2011 - Val Brickates Kennedy
Stocks to watch Tuesday: Exelixis, DirecTV, Leap 6:46 a.m. Nov. 1, 2011 - MarketWatch
Exelixis slides, Allstate up in after-hours trade 6:48 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis shares fall without FDA study commentary 6:05 p.m. Oct. 31, 2011 - Wallace Witkowski
Exelixis shares resume trading, drop 35% 5:44 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis rallies 21% on drug study 11:46 a.m. Oct. 24, 2011 - Val Brickates Kennedy
Icahn reports new stakes in Vector Group, El Paso 7:52 p.m. Aug. 15, 2011 - MarketWatch.com
ASCO studies shake up drug stocks 4:17 p.m. June 7, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 6:50 p.m. June 6, 2011 - Kate Gibson
Exelixis, Sunesis lead drug stocks lower 3:42 p.m. June 6, 2011 - Val Brickates Kennedy
Exelixis sinks 18% on drug-safety concerns 3:21 p.m. June 6, 2011 - Val Brickates Kennedy
Notable earnings after Thursday close 5:35 p.m. April 30, 2014 - Seeking Alpha
First Week Of June 21st Options Trading For Exelixis (EXEL) 11:19 a.m. April 23, 2014 - TheStreet.com
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog 10:43 a.m. April 2, 2014 - Zacks.com
Exelixis' Cometriq Approved in the EU - Analyst Blog 6:00 p.m. March 27, 2014 - Zacks.com
Trade-Ideas: Exelixis (EXEL) Is Today's "Dead Cat Bounce" Stock 9:45 a.m. March 27, 2014 - TheStreet.com
Interesting EXEL Put And Call Options For November 22nd 12:13 p.m. March 26, 2014 - TheStreet.com
Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis 11:42 a.m. March 26, 2014 - TheStreet.com
Exelixis Enters the Danger Zone 11:35 a.m. March 26, 2014 - 247WallSt.com
Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis Shares Decline 11:28 a.m. March 26, 2014 - benzinga.com
Exelixis Urged to Continue Studying Prostate Cancer Treatment 9:27 a.m. March 26, 2014 - The Wall Street Journal Interactive Edition
Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast 9:24 a.m. March 26, 2014 - benzinga.com
Stocks Hitting 52-Week Lows 9:22 a.m. March 26, 2014 - benzinga.com
Exelixis (EXEL) Trading With Heavy Volume Before Market Open 8:46 a.m. March 26, 2014 - TheStreet.com
Exelixis trial for prostate-cancer drug given OK to continue 7:37 a.m. March 26, 2014 - Seeking Alpha
4 Reasons To Be Bullish On Exelixis In The Near Term 10:11 a.m. March 25, 2014 - Seeking Alpha
'Mad Money' Lightning Round: I Want to Buy Time Warner 6:00 a.m. March 14, 2014 - TheStreet.com
Cramer's Lightning Round - I Don't Know What Annaly Is Up To (3/13/14) 5:23 a.m. March 14, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Us vs. Them 7:58 p.m. March 13, 2014 - TheStreet.com
Exelixis Q4 Loss In Line with Expectations - Analyst Blog 12:04 p.m. Feb. 21, 2014 - Zacks.com
Exelixis CEO Discusses Q4 2013 Results - Earnings Call Transcript 11:37 p.m. Feb. 20, 2014 - Seeking Alpha
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014 4:07 p.m. April 21, 2014 - BusinessWire - BZX
Thyroid Cancer Global Clinical Trials Review, H2, 2013 1:29 p.m. April 9, 2014 - PR Newswire - PRF
European Commission Approves Exelixis Inc.'s Therapy for Thyroid Cancer 2:01 p.m. April 4, 2014 - ACCESSWIRE
King Digital Crushed In Its First Day of Trading; Exelixis Shares Fall 40 Percent 12:11 a.m. March 27, 2014 - ACCESSWIRE
Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer 7:18 p.m. March 25, 2014 - BusinessWire - BZX
Cometriq(R) approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. 7:02 a.m. March 25, 2014 - Thomson Reuters ONE
Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma 6:01 a.m. March 25, 2014 - BusinessWire - BZX
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus 10:46 a.m. March 24, 2014 - PR Newswire - PRF
Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference 8:56 p.m. Feb. 26, 2014 - BusinessWire - BZX
Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results 5:15 p.m. Feb. 20, 2014 - BusinessWire - BZX
Exelixis Appoints Executive Vice President and General Counsel 6:27 p.m. Feb. 12, 2014 - BusinessWire - BZX
Exelixis Announces February 20th Webcast of Fourth Quarter and Full Year 2013 Financial Results Conference Call 5:35 p.m. Feb. 10, 2014 - BusinessWire - BZX
Exelixis Announces Webcasts of Investor Conference Presentations in February 6:48 p.m. Jan. 31, 2014 - BusinessWire - BZX
Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock 9:33 a.m. Jan. 23, 2014 - BusinessWire - BZX
Exelixis Launches Proposed Overnight Public Offering of Common Stock 5:01 p.m. Jan. 22, 2014 - BusinessWire - BZX
Honigman leads client to victory in U.S. Court of Appeals patent term adjustment ruling 8:08 a.m. Jan. 17, 2014 - GlobeNewswire
Unaudited Results, Partnerships, and Stock Price Movements - Research Report on Cubist, Novavax, Exelixis, BioCryst, and Foundation Medicine 9:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
Upcoming Conference Participations, Cash Dividends, and Share Price Movements - Research Report on Johnson & Johnson, Boston Scientific, NuVasive, Exelixis, and Healthways 9:00 a.m. Jan. 7, 2014 - PR Newswire
Clinical Study Results, Pending Applications, Trial Updates, and Discontinued Trials - Research Report on ICU Medical, Exelixis, Cempra, Exact Sciences, and Onconova 9:00 a.m. Dec. 25, 2013 - PR Newswire
(0)
(0)Scroll down for more posts ▼